Table 5.
Hazard Ratios for Subgroup, Sensitivity, and Additional Analyses for Muscular Events in the Primary Prevention Cohorts After Propensity Score Matching
| Number of events | Total person-years of follow-up | HR (95% CI) | |||
|---|---|---|---|---|---|
| Exposed | Comparator | Exposed | Comparator | ||
| Low-intensity statin therapy | |||||
| Pravastatin vs simvastatin (ref) | |||||
| Subgroup analyses | |||||
| Male | 33 | 46 | 3,860 | 3,938 | 0.73 (0.47–1.14) |
| Female | 49 | 51 | 3,711 | 3,860 | 0.99 (0.67–1.47) |
| 40–64 years | 39 | 58 | 3,903 | 4,028 | 0.69 (0.46–1.04) |
| ≥65 years | 43 | 54 | 3,665 | 3,743 | 0.81 (0.54–1.21) |
| 20 vs 10 mg | 35 | 49 | 3,458 | 3,562 | 0.73 (0.47–1.13) |
| 40 vs 20 mg | 47 | 59 | 4,110 | 4,258 | 0.82 (0.56–1.21) |
| Sensitivity analyses | |||||
| No muscle complaints before CED | 71 | 98 | 6,932 | 7,120 | 0.74 (0.55–1.01) |
| No use of CYP3A4 inhibiting drugs* | 57 | 69 | 5,272 | 5,463 | 0.85 (0.60–1.21) |
| Additional analyses | |||||
| Censoring if dosage change | 75 | 88 | 7,034 | 6,966 | 0.85 (0.62–1.15) |
| Broader outcome definition† | 99 | 145 | 7,577 | 7,852 | 0.70 (0.54–0.91) |
| Moderate- to high-intensity statin therapy | |||||
| Rosuvastatin vs atorvastatin (ref) | |||||
| Subgroup analyses | |||||
| Male | 42 | 36 | 2,744 | 2,773 | 1.18 (0.76–1.84) |
| Female | 57 | 43 | 2,862 | 2,905 | 1.34 (0.90–1.99) |
| 40–64 years | 59 | 44 | 3,448 | 3,478 | 1.35 (0.92–2.00) |
| ≥65 years | 42 | 23 | 2,122 | 2,141 | 1.84 (1.11–3.06) |
| 5–10 vs 10–20 mg | 95 | 70 | 5,426 | 5,490 | 1.37 (1.01–1.87) |
| 20–40 vs 40–80 mg | X | 5 | 188 | 184 | 0.59 (0.14–2.47) |
| Sensitivity analyses | |||||
| No muscle complaints before CED | 88 | 74 | 5,179 | 5,238 | 1.20 (0.88–1.64) |
| No use of CYP3A4 inhibiting drugs* | 79 | 63 | 4,460 | 4,475 | 1.26 (0.90–1.75) |
| Additional analyses | |||||
| Censoring if dosage change | 96 | 84 | 5,395 | 5,196 | 1.11 (0.83–1.48) |
| Broader outcome definition† | 120 | 108 | 5,628 | 5,658 | 1.12 (0.86–1.45) |
| Simvastatin vs atorvastatin (ref) | |||||
| Subgroup analyses | |||||
| Male | 215 | 152 | 14,952 | 15,144 | 1.43 (1.16–1.76) |
| Female | 279 | 204 | 14,204 | 14,494 | 1.39 (1.16–1.67) |
| 40–64 years | 251 | 198 | 16,280 | 16,638 | 1.29 (1.07–1.56) |
| ≥65 years | 238 | 159 | 12,753 | 12,910 | 1.52 (1.24–1.85) |
| 40 vs 10 mg | 502 | 352 | 28,972 | 29,517 | 1.45 (1.27–1.66) |
| 80 vs 20 mg | X | X | 191 | 197 | 1.01 (0.20–5.01) |
| Sensitivity analyses | |||||
| No muscle complaints before CED | 413 | 287 | 26,347 | 26,782 | 1.46 (1.26–1.70) |
| No use of CYP3A4 inhibiting drugs* | 349 | 290 | 21,661 | 21,932 | 1.22 (1.04–1.42) |
| Additional analyses | |||||
| Censoring if dosage change | 468 | 335 | 27,920 | 27,451 | 1.38 (1.20–1.59) |
| Broader outcome definition† | 697 | 534 | 29,222 | 29,708 | 1.33 (1.18–1.48) |
HR hazard ratio, CI confidence interval, Ref reference, CED cohort entry date, CYP3A4 Cytochrome P450 3A4; X cell contains <5 patients (not shown owing to ethics regulations to preserve confidentiality)
*The analysis was restricted to patients with no prescription for azole antifungals, macrolide antibiotics, cimetidine, cyclosporine, nefazodone, amiodarone, amlodipine, diltiazem, and verapamil within 180 days before the cohort entry date. We censored patients on the day of a first prescription for one of the drugs during follow-up
†Any recorded Read code for “statin intolerance” qualified as an outcome of interest